twitter   linkedin

11421 Saskatchewan Drive Edmonton, AB, Canada T6G2M9 info@kmthepatech.com

KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.

The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.

We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies
The KMT MouseTM is your essential tool for therapeutics and vaccine development.

News and Events

  1. SOT logo small

    SOT 2015 Meeting and ToxExpo

    March 13 2015

    Check our Poster on March 26, 2015 at the Society of Toxicology Annual Meeting

  2. BIO-Europe Spring logo

    BIO-Europe Spring 2015

    February 06 2015

    KMT Hepatech to attend BIO-Europe Spring on March 9-11, 2015

  3. Efficacy graph

    Hepatitis B in vivo service

    November 17 2014

    Efficacy studies with Tenofovir and Entecavir and updated information on HBV in vivo services

  4. »more